- Open Access
Organ-, inflammation- and cancer specific transcriptional fingerprints of pancreatic and hepatic stellate cells
Molecular Cancer volume 9, Article number: 88 (2010)
Tissue fibrosis is an integral component of chronic inflammatory (liver and pancreas) diseases and pancreatic cancer. Activated pancreatic- (PSC) and hepatic- (HSC) stellate cells play a key role in fibrogenesis. To identify organ- and disease-specific stellate cell transcriptional fingerprints, we employed genome-wide transcriptional analysis of primary human PSC and HSC isolated from patients with chronic inflammation or cancer.
Stellate cells were isolated from patients with pancreatic ductal adenocarcinoma (n = 5), chronic pancreatitis (n = 6), liver cirrhosis (n = 5) and liver metastasis of pancreatic ductal adenocarcinoma (n = 6). Genome-wide transcriptional profiles of stellate cells were generated using our 51K human cDNA microarray platform. The identified organ- and disease specific genes were validated by quantitative RT-PCR, immunoblot, ELISA, immunocytochemistry and immunohistochemistry.
Expression profiling identified 160 organ- and 89 disease- specific stellate cell transcripts. Collagen type 11a1 (COL11A1) was discovered as a novel PSC specific marker with up to 65-fold higher expression levels in PSC compared to HSC (p < 0.0001). Likewise, the expression of the cytokine CCL2 and the cell adhesion molecule VCAM1 were confined to HSC. PBX1 expression levels tend to be increased in inflammatory- vs. tumor- stellate cells. Intriguingly, tyrosine kinase JAK2 and a member of cell contact-mediated communication CELSR3 were found to be selectively up-regulated in tumor stellate cells.
We identified and validated HSC and PSC specific markers. Moreover, novel target genes of tumor- and inflammation associated stellate cells were discovered. Our data may be instrumental in developing new tailored organ- or disease-specific targeted therapies and stellate cell biomarkers.
Emerging body of data suggest a critical role for stellate cells in the pathophysiology of pancreatic cancer and chronic inflammatory diseases [1–5]. Hepatic stellate cells (HSC) were first described by Karl von Kupffer in 1876, however similar cells in the pancreas were first observed in 1980s [1, 3, 6]. In 1998 Bachem and Apte isolated and cultured pancreatic stellate cells (PSC) [7, 8]. Morphologic, functional and gene expression studies revealed that PSC resemble HSC characteristics and therefore may possibly share a common origin [3, 9]. However, the origin of stellate cells is still controversially debated. Mesenchymal [10, 11], endodermal [12, 13] as well as neuroectodermal origins [14–16] are suggested. Further, it is postulated that in the diseased organ, stellate cells are transformed from their quiescent precursors, or recruited from local fibroblasts, bone marrow derived cells or generated via epithelial-mesenchymal transformation [1, 3, 17].
HSC represent 5-8% of all human liver cells and reside in the space of Disse . In contrast to quiescent HSC, activated HSC lack cytoplasmic lipid droplets containing retinyl esters and long cytoplasmic processes. Their activation or trans-differentiation is regulated by paracrine and autocrine loops of growth factors which are associated with pathological conditions such as liver injury, cirrhosis and cancer [1, 2]. Stellate cell over-activity can severely impair organ function due to excessive contraction and abundant extracellular matrix protein deposition. Moreover, it is becoming clearer that myofibroblasts found in the activated stroma of epithelial tumors significantly impact tumor behavior [5, 18]. Tumor-stroma interactions influence both the progression of cancer and tumor responses to cancer therapies [4, 5, 18–21]. Since conventional therapies are far from cure, new targeted therapies appear as promising alternatives or adjuncts . Indeed, the tumor microenvironment and the desmoplastic reaction observed in pancreatic ductal adenocarcinoma (PDAC) have attracted enormous scientific attention and emerged as a critical therapeutic target [19, 23, 24].
To selectively and specifically target HSC or PSC in chronic inflammatory diseases or in cancer, a better molecular characterization of these cells is required. In an attempt to identify organ- and disease-specific transcripts, we isolated stellate cells from a total of 22 patients with primary PDAC, chronic pancreatitis, liver cirrhosis, and liver metastasis of PDAC. Genome-wide transcriptional analysis was employed and novel candidate tumor-, inflammation- or organ-specific stellate cell genes were identified and validated in the tissues of these patients by real time quantitative RT-PCR, immunohistochemistry, immunocytochemistry, ELISA and immunoblot analyses.
Materials and methods
Pancreatic tissues and human pancreatic stellate cell cultivation
The use of human material for the analysis was approved by the local ethics committee of the University of Heidelberg, Germany, and written informed consent was obtained from all patients. Sterile tissues were obtained immediately after surgical resection from five patients with PDAC, six patients with chronic pancreatitis (CP), five patients with liver cirrhosis (LC) that underwent liver transplantation, and six patients with liver metastasis (LM) of pancreatic cancer. During tissue collection, freshly removed samples were either snap frozen in liquid nitrogen and stored at -80°C for protein and DNA extraction or preserved in RNA-later solution for future RNA extraction. A portion of the samples was also fixed in 4% parafomaldehyde solution for 12-24 h and then embedded in paraffin for histological analysis. Human stellate cell isolation and cultivation were performed under sterile conditions for all cell types by using the outgrowth method as described initially by Bachem et al. . Briefly; passage-1 was described as the first lot of cells growing out from fibrotic blocks of pancreatic tissues seeded in 10 cm Petri dishes. To prevent bias, the number of blocks was kept constant (30 blocks with 2-3 mm diameter/per 75 cm2). Passage-2 is a 1:2 division of these cells into two new T75 cm2 flasks. When passage-2 cells reached confluency, they were aliquoted and frozen. All cells used were passage-3 after thawing a clone of frozen passage-2. Purity of stellate cells was routinely checked by immunocytochemistry and immunofluorescence analyses (Additional file1). All passages used were controlled and no morphologically different subpopulation was detected.
Total RNA isolation
To prevent passage dependent variations, third passages of PSC and HSC were used for all analyses. Total RNA from 80% confluent stellate cells in 10 cm Petri dishes was isolated by organic extraction with the phenolic Trizol reagent as described . The Agilent 2100 Bioanalyzer (Agilent Technologies Inc. Santa Clara, CA) was used for the quality control of the isolated total RNA and amplified RNA (aRNA) by capillary electrophoretic separation .
Genome-wide expression profiling
Genome-wide expression profiling was done using 51K Human Unigene III cDNA microarrays. The microarrays were designed, generated, and hybridized as described previously [24, 26, 27]. Each sample was hybridized against Human Universal Reference Total RNA (# 636538, BD Clontech, Heidelberg, Germany). Expression profiling was performed as previously described with minor modifications [24, 26, 27]. Linear amplification from 2 μg total RNA was performed using the "MessageAmp II aRNA Amplification Kit" (Ambion, #1751). From amplified RNA, 5 μg were used for indirect labeling by incorporation of aminoallyl modified nucleotides and chemical attachment of free reactive fluorescent Cy3- or Cy5-dye (Atlas Glass fluorescent labelling kit, BD Biosiences Catalogue #K1037-1; Cy5-dye, Cy3-dye, GE Healthcare UK Limited, #Q15108, #Q13108). Corresponding Cy3- and Cy5- labeled probes and competitor DNA (5 μg human Cot-DNA, Invitrogen; 5 μg poly-dA, Amersham) were combined, diluted in hybridization buffer to a final volume of 80 μl (50% Formamide, 6× SSC, 0.5% SDS, 5× Denhards), and denatured for 5 min at 95°c prior to hybridization. Prehybridization was performed at 42°C for 20 min in 6× SSC, 0.5% SDS, 1% BSA. Slides were rinsed in H2O and spotted probes were denatured by incubating the slide for 2 min in 90°C H2O. Hybridization probe was added and static hybridization performed at 42°C for 16 h. Excess of probe was removed by washing in 2 × SSC, 0.5%SDS at 42°C for 5 min, then in 0.2 × SSC, 0.5%SDS at 42°C for 15 min and finally in isopropanol for 30s at RT. Slides were scanned with Agilent Microarray Scanner and image processing was done using the "Chipskipper" software. Data were stored in MO-MEX database Bloader that enables direct submission of large batches of MIAME complaint expression profiling data to the ArrayExpress database. Microarray data are available online at ArrayExpress http://www.ebi.ac.uk/arrayexpress under the accession no. E-TABM-625.
Statistical analysis of the microarray data
Generation of expression matrices, data annotation, filtering, and processing were done using TableButler software package http://www.oncoexpress.de/software/tablebutler. All microarray statistics including t-test with permutation analysis, Pavlidis template matching (PTM), and cluster analysis were done using the Java based software package TIGR MultiExperiment Viewer (TMEV) version 3.01 http://www.tm4.org/mev.html. Genes were defined as differentially expressed between two sets of samples if a two-class permutation based t-test (number of permutations = 1000) yielded a p-value of less than 0.05 after standard Bonferroni correction for multiple hypothesis testing. Subsequently, regulated genes were sorted by hierarchical clustering (HCL). PTM allows the specification of a template expression profile for a gene by designating relative gene expression ratios for each condition. The data sets are searched for matches to this template, i.e. for the specific expression pattern. Gene expression data were filtered for genes that matched each template based on a Pearson correlation coefficient r ≥ 0.70. The obtained gene expression profiles were visualized as heatmaps.
Real time quantitative PCR
All reagents and equipment for mRNA/cDNA preparation were purchased from Roche Applied Science Diagnostics (Mannheim, Germany). mRNA extractions were prepared by automated isolation using the MagNA Pure LC instrument and isolation kit I. cDNA was prepared using the first-strand cDNA synthesis kit (AMV) according to the manufacturer's instructions. Real-time PCR was performed with the Light Cycler Fast Start DNA SYBR Green kit. All primers were obtained from Search-LC (Heidelberg, Germany). The calculated number of specific transcripts was normalized to 10,000 copies of the housekeeping gene PPIB (peptidylprolyl isomerase B, also known as cyclophilin B), and expressed as number of copies per μl of input cDNA. Statistical comparisons were made by Mann-Whitney U test. A P-value less than 5% was regarded as significant.
Immunohistochemistry and immunocytochemistry analyses
Immunoblot analysis and densitometry
To keep passage dependent variations at minimum, third passages of PSC and HSC were used for analysis. Stellate cells were grown in Petri dishes until 80% confluency under standard conditions. Protein extraction was carried out as published before . Immunoblot analyses and the densitometric analysis of the blots were done as described previously . Antibodies used and the appropriate dilution are shown in Table 1. Graphic results are expressed after normalization to the housekeeping gene GAPDH as percent change of the appropriate control.
Cells were grown in 10-cm plates until 80% confluence. Serum free medium was kept on the cells for 48 h. Supernatants and total cell lysates were extracted and frozen at -80°C until use. For the quantification of CCL2, a commercially available ELISA kit (Human MCP-1 ELISA, 555179, BD Biosciences, Heidelberg, Germany) was used according to the manufacturers' recommendations.
Evaluation of gene expression profiles
Morphology and purity of stellate cells was routinely checked by immunocytochemistry (Additional file1). In order to identify organ and disease specific transcriptome signatures of stellate cells, a microarray analysis was made (Figure 1, Figure 2). The obtained gene expression profiles were visualized as heatmaps (Figure 3, Figure 4). Red signifies high gene expression, while black signifies intermediate gene expression and green signifies low gene expression of the corresponding gene compared to the reference, respectively. Each row represents one gene, each column represents one sample. The dendrograms on the left side of the heat maps define how the genes cluster after applying hierarchical cluster analysis (average linkage). Expressions of genes are expressed using log2 ratios, where the +/- sign indicates which channel had the higher intensity. Hence, an expression ratio of +2 represents a 4-fold up-regulation of a gene under condition A compared to this gene under condition B, an expression ratio of -2 represents a 4-fold down-regulation.
Organ specific profile
A total of 160 annotated genes were identified as differentially expressed between pancreas and liver derived stellate cells. To obtain a clear and well-defined matrix, these genes were compared as: downregulated in pancreatic stellate cells in comparison to hepatic stellate cells (n = 80, Figure 3B) or upregulated in pancreatic stellate cells in comparison to hepatic stellate cells (n = 80, Figure 3C). A group of selected genes are presented in Table 2. Significantly different genes in each group with high differential expression ratios were further analyzed by quantitative real time PCR, immunoblotting, immunocytochemistry and immunohistochemistry in all patients.
Pancreatic stellate cell specific genes
In this group, collagen type XI alpha 1 (Col11a1) was the most specific gene with a 13.74-fold upregulation in PSC compared to HSC. In concordance with the array data, Col11a1 was highly pancreas specific with its average mRNA expression being 65-fold (p < 0.0001) higher in the PSC compared to that of HSC as determined by qRT-PCR (Figure 5A). Since there was no suitable antibody for immunoblot analysis, the expression of Col11a1 in tissues and in cultured stellate cells was evaluated by immunohistochemistry and immunocytochemistry. In all patients, PSC showed a specific staining while HSC remained Col11a1 negative by immunohistochemistry. Co-localization of alpha-smooth muscle actin (red) and Col11a1 (green) in stellate cells in pancreatic tissues is shown by immunofluorescence analysis (Figure 5B). There was also a weak staining in pancreatic acini and hepatocytes (Figure 5C-H). Verification of Col11a1 protein expression in cultured stellate cells by immunocytochemistry showed also a PSC specific staining (Figure 6).
Hepatic stellate cell specific genes
In this group, some genes showed a high HSC specificity. Vascular cell adhesion molecule 1 (VCAM1) was 5.05-fold upregulated in HSC compared to PSC and chemokine (C-C motif) ligand 2 (CCL2) was 2.96-fold upregulated in HSC compared to PSC. In line with the microarray data compared to their average expressions in PSC, VCAM1 and CCL2 mRNA expressions were 5.66-fold (p = 0.0016) and 2.28-fold (p = 0.0020) higher in HSC as determined by qRT-PCR, respectively (Figure 7A & Figure 8D). Next, to quantify the protein expression in vitro, cell lysates of cultured human stellate cells (n = 4 per pathology) were analyzed by immunoblotting or ELISA. Protein expression of VCAM1 in cultivated stellate cells mirrored its mRNA expression. Densitometric analysis of samples showed a 4.71-fold (p = 0.028) higher expression in HSC compared to that of PSC (Figure 7B). Since there was no suitable antibody for immunoblot analysis for CCL2, quantification was made by ELISA. Similar to VCAM1 expression, CCL2 also showed a HSC specific expression irrespective of the pathology (3.15-fold, p = 0.024, Figure 8E). In the last step, we verified the localization of these proteins in human tissues. Liver cirrhosis tissues were probed with alpha-smooth muscle actin (Figure 8A) or VCAM-1 (Figure 8B). Co-localization of alpha-smooth muscle actin (red) and VCAM-1 (green) in stellate cells (orange) in hepatic tissues is shown by immunofluorescence analysis (Figure 8C). All patients showed various degrees of VCAM1 expression. Although immunohistochemistry showed specific staining in stellate cells, there was no obvious organ predilection. In addition to stellate cells, pancreatic cancer cells, hepatocytes and some inflammatory cells were also positive for VCAM1 (Figure 7C-H).
Disease specific profile
Microarray analysis further identified a total of 89 annotated genes as differentially expressed between stellate cells derived from inflammatory and malignant conditions (Figure 2). To obtain a clear and well-defined matrix, these genes were sorted by two given expression profiles as: downregulated in stellate cells of inflamed tissues compared to stellate cells of tumor tissues (n = 25, Figure 4B) or upregulated in inflamed tissue compared to tumor tissues (n = 64, Figure 4C). Significantly different genes in each group with high differential expression ratios were further analyzed by quantitative real time PCR, immunoblotting, immunocytochemistry and immunohistochemistry in all patients. A group of selected genes are presented in Table 3.
Tumor specific genes
Microarray analysis showed that some genes displayed a cancer specific pattern irrespective of the organ the stellate cells were derived from. For example, cadherin EGF LAG seven-pass G-type receptor 3 (CELSR3) was 3.04-fold upregulated in tumor associated stellate cells compared to inflammation associated stellate cells. Similarly, its mRNA expression was 123% higher (p = 0.004) in the cancer associated stellate cells as determined by qRT-PCR (Figure 9A). By immunoblot analysis, CELSR3 protein was expressed at 83% higher levels (p = 0.030) in tumor related stellate cells compared to that of inflammation related stellate cells (Figure 9B). There was also a disease specific expression of CELSR3 expression in tissues (Figure 9C-F). While hepatocytes were mostly unstained some pancreatic acini and pancreatic cancer cells were also positive for CELSR3.
Inflammation specific genes
In the microarray analysis, pre-B-cell leukemia transcription factor 1 (Pbx1) was 1.7-fold upregulated in inflammation associated stellate cells compared to tumor associated stellate cells. Although the differences did not reach statistical significance, Pbx1 expression was also 98% higher (p = 0.107) in inflammation associated stellate cells as determined by qRT-PCR (Figure 10A). Similarly, the protein expression of Pbx1 was also 64% higher in stellate cells derived from inflammatory pathologies compared to that of tumor derived stellate cells (p = 0.70, Figure 10B). Although partly discrepant with the immunoblot analysis, this tendency was also visible by immunohistochemistry analysis (Figure 10C-F). In addition to stellate cells, tubular complexes in pancreatic tissues and bile ducts in the liver parenchyma also displayed some Pbx1 positivity.
Here we report the identification of novel tumor stellate cell specific genes and proteins. In addition, hepatic vs. pancreatic stellate cell specific transcripts were discovered. The mRNA and protein expression levels of candidate genes identified by genome-wide transcriptional analysis were confirmed by qRT-PCR, ELISA and Immunoblot analyses. The specific expression pattern of the candidate proteins was further assured in-vitro by immunocytochemistry of isolated stellate cells and ex-vivo by immunohistochemistry of formalin fixed paraffin embedded tissues. The identified molecular fingerprint of stellate cells might be instrumental in development of novel biomarkers and rational design of therapeutic strategies aiming to selectively target cancer or inflammation associated stellate cells. One drawback of this study is the absence of a third comparator, namely stellate cells from the normal pancreas and liver. However, stellate cells from the normal pancreas do not grow efficiently when propagated by the outgrowth method. Neither could stellate cells from fibrotic tissues like chronic pancreatitis and pancreatic cancer be efficiently propagated by collagenase digestion and centrifugation. The yield of the latter method is very low in comparison to the outgrowth method. Therefore the authors have decided to use only one stellate cell propagation method (outgrowth) to prevent bias that may result from differences in methodology. As a trade-off, a comparator (normal stellate cells) could not be used.
Among the here identified tumor stellate cell specific genes, JAK2 and CELSR3 pose interesting targets for developing therapeutic strategies. Aberrant JAK2 signaling has been linked to myeloproliferative disorders such as polycythemia vera and chronic myelogenous leukemia [31, 32]. Small molecular inhibitors of JAK2 signaling have already entered clinical trials. Therefore the role of JAK2 overexpression in PSC of PDAC tumors remains to be functionally elucidated. Upregulation of CELSR3 in tumor PSC could also provide a potential druggable target since the protein encoded by this gene is located at the plasma membrane and has intriguing signaling capabilities . CELSR3 is a member of the flamingo protein subfamily which is part of the cadherin superfamily. The flamingo cadherins have nine cadherin domains, seven epidermal growth factor-like repeats and two laminin A G-type repeats in their ectodomain . It is postulated that these proteins are receptors involved in contact-mediated communication, with cadherin domains acting as homophilic binding regions and the EGF-like domains involved in cell adhesion and receptor-ligand interactions. Together, these data suggest an important role for CELSR3 in tumor stellate cells that warrants further investigation.
Recent studies have reported differential regulation of genes in murine and human stellate cells throughout their activation process and under certain drug therapies. Although these studies provide valuable information, a careful interpretation of their data is warranted. First, murine stellate cells may not reflect the situation in humans due to interspecies differences. Second, stellate cells show a great variance depending on the donor, therefore a weakness of the past studies might be the limited number of patients' stellate cells investigated to cover the inter-individual heterogeneity. Our report constitute one of the most comprehensive studies on stellate cell transcriptome using 22 different human donors, thus diminishing potential patient specific biases. This might be a plausible explanation for the success of our approach to identify organ- and disease-specific stellate cell transcriptome. In contrast to the studies comparing quiescent vs. activated stellate cells, we compared human stellate cells that were activated in-vivo either by chronic inflammation or cancer. Currently there is no information on how the "ancestral microenvironmental activity" of stellate cells affects their transcriptome after in-vitro cultivation. Therefore, the identified tumor stellate cell specific genes e.g. CELSR3 might provide a favorable therapeutic profile to selectively target tumor stroma while sparing the stellate cell activity under physiological conditions.
It has been reported that experimental ablation of tumor associated fibroblasts or down-regulation of the hedgehog-signalling pathway in the pancreatic tumor stroma decreased cancer cell growth and greatly increased intra-tumoral uptake of chemotherapeutic drugs in murine models of colon, breast cancer an pancreatic cancers [5, 35]. It is likely that targeting the stroma in order to uncouple stromal-cancer cell interactions may interrupt multiple aberrant autocrine and paracrine pathways that promote pancreatic cancer cell growth, invasion and metastasis [4, 21]. Currently, there is no stellate cell specific promoter known to specifically target the stromal cells in the liver or pancreas. Moreover, the similarities between PSC and HSC make it very difficult to target one population without creating side-effects on the other one. For example, the usage of retinoids seems promising in deactivating PSC in-vitro. In contrast, treatment with retinoids were shown to provoke fibrogenic effects in HSC, thus, limiting its efficient systemic use in the clinical setting .
In this context, our data provide valuable information focusing on the subtle but important differences of liver vs. pancreatic stellate cells that exist rather than their similarities. We found collagen type 11a1 expression to be highly specific for the PSC and almost absent in HSC. Type XI collagen is a minor fibril-forming collagen that assists in proper type II collagen fibril formation . Col11a1 is mainly expressed in articular cartilage and the vitreous fluid of the eye [39–43]. During embryogenesis, Col11a1 expression is also detectable in many other human fetal tissues including the bone . Marshall and type II Stickler syndromes are genetically transmitted diseases that are caused by mutations in Col11a1 gene manifested with sensory and skeletal abnormalities [44, 45]. In Col11a1 knockout mice, chondrocytes fail to fully differentiate causing a chondrodystrophic phenotype with skeletal abnormalities. These data show that Col11a1 is essential for skeletal morphogenesis because it controls type II collagen fibrillogenesis, chondrocyte maturation and bone mineralization [46, 47]. Importantly, in adult life these tissues are not undergoing dynamic changes. Therefore Coll11a1 may provide an interesting target for conditional knockout to target PSC in order to assess PSC contribution in conditions like chronic pancreatitis or pancreatic cancer.
Buchholz et al. compared gene expression of human HSC, PSC and skin fibroblasts . Their data show that, compared to dermal fibroblasts, HSC and PSC exhibit great similarities in their transcriptional phenotypes and possibly share a common origin [3, 9]. Indeed, HSC and PSC are activated by common cytokines, growth factors and alcohol metabolites during development of tissue fibrosis [3, 7, 30, 48–50]. However, the fundamental differences in their microenvironments may condition these cells to differentially respond to organ injury and cancer [1, 3, 30]. For example, in contrast to hepatocellular carcinoma, desmoplasia is a typical feature of pancreatic ductal adenocarcinoma. This difference may result in part due to the release of potent fibrogenic mediators by pancreatic cancer cells [1, 19, 30, 51]. We have previously shown that, compared to the primary tumor, liver metastasis of PDAC elicit a weaker fibrogenic response in the HSC that surround them. This observation can be due to the differences of HSC and PSC, or it could, considering the temporal sequence of events, merely reflect a shorter cancer-HSC interaction . Interestingly, we found almost twice as much differentially regulated genes with an organ specific expression pattern as compared to chronic inflammation or tumor related genes. Moreover, differences in gene expression levels between HSC and PCS were more pronounced compared to disease specific stellate cells. These differences can be due to various factors. It may reflect that PSC and HSC do not share a common origin, or it may also suggest that chronic inflammation and cancer develop in similar microenvironments created by the activated stroma of the respective organs.
In the clinical setting, chronic inflammatory conditions of the liver (cirrhosis) and pancreas (chronic pancreatitis) not only increase the incidence of cancer, but also constitute diagnostic hurdles. Biopsies that do not show tumor structures are not helpful in diagnosis since they are useless in exclusion of the tumor. However, identification of tumor versus inflammation specific signatures of the stroma may increase diagnostic accuracy of biopsies even where tumor tissue is missed.
Conclusively, identification of inherent and acquired differences in stellate cell transcriptome will improve current understanding of stellate cell pathophysiology and may facilitate the discovery of novel selective therapeutic targets. Our data provide a new platform to understand and possibly interfere with organ or disease specific responses of stellate cells. Further research is warranted to analyze the importance of these findings at functional levels.
Conflict of interests
The authors declare that they have no competing interests.
Hepatic stellate cells
Pancreatic ductal adenocarcinoma
Pancreatic stellate cells.
Friedman SL: Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008, 88: 125-172. 10.1152/physrev.00013.2007
Friedman SL: Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008, 134: 1655-1669. 10.1053/j.gastro.2008.03.003
Omary MB, Lugea A, Lowe AW, Pandol SJ: The pancreatic stellate cell: a star on the rise in pancreatic diseases. J Clin Invest. 2007, 117: 50-59. 10.1172/JCI30082
Erkan M, Reiser-Erkan C, Michalski CW, Deucker S, Sauliunaite D, Streit S, Esposito I, Friess H, Kleeff J: Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia. 2009, 11: 497-508.
Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D: Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009, 324: 1457-1461. 10.1126/science.1171362
Watari N, Hotta Y, Mabuchi Y: Morphological studies on a vitamin A-storing cell and its complex with macrophage observed in mouse pancreatic tissues following excess vitamin A administration. Okajimas Folia Anat Jpn. 1982, 58: 837-858.
Apte MV, Haber PS, Applegate TL, Norton ID, McCaughan GW, Korsten MA, Pirola RC, Wilson JS: Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. Gut. 1998, 43: 128-133. 10.1136/gut.43.1.128
Bachem MG, Schneider E, Gross H, Weidenbach H, Schmid RM, Menke A, Siech M, Beger H, Grunert A, Adler G: Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology. 1998, 115: 421-432. 10.1016/S0016-5085(98)70209-4
Buchholz M, Kestler HA, Holzmann K, Ellenrieder V, Schneiderhan W, Siech M, Adler G, Bachem MG, Gress TM: Transcriptome analysis of human hepatic and pancreatic stellate cells: organ-specific variations of a common transcriptional phenotype. J Mol Med. 2005, 83: 795-805. 10.1007/s00109-005-0680-2
Asahina K, Tsai SY, Li P, Ishii M, Maxson RE, Sucov HM, Tsukamoto H: Mesenchymal origin of hepatic stellate cells, submesothelial cells, and perivascular mesenchymal cells during mouse liver development. Hepatology. 2008.
Enzan H, Himeno H, Hiroi M, Kiyoku H, Saibara T, Onishi S: Development of hepatic sinusoidal structure with special reference to the Ito cells. Microsc Res Tech. 1997, 39: 336-349. 10.1002/(SICI)1097-0029(19971115)39:4<336::AID-JEMT4>3.0.CO;2-F
Kiassov AP, Van Eyken P, van Pelt JF, Depla E, Fevery J, Desmet VJ, Yap SH: Desmin expressing nonhematopoietic liver cells during rat liver development: an immunohistochemical and morphometric study. Differentiation. 1995, 59: 253-258. 10.1046/j.1432-0436.1995.5940253.x
Vassy J, Rigaut JP, Briane D, Kraemer M: Confocal microscopy immunofluorescence localization of desmin and other intermediate filament proteins in fetal rat livers. Hepatology. 1993, 17: 293-300. 10.1002/hep.1840170221
Cassiman D, Roskams T: Beauty is in the eye of the beholder: emerging concepts and pitfalls in hepatic stellate cell research. J Hepatol. 2002, 37: 527-535. 10.1016/S0168-8278(02)00263-5
Friedman SL: Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 2000, 275: 2247-2250. 10.1074/jbc.275.4.2247
Niki T, Pekny M, Hellemans K, Bleser PD, Berg KV, Vaeyens F, Quartier E, Schuit F, Geerts A: Class VI intermediate filament protein nestin is induced during activation of rat hepatic stellate cells. Hepatology. 1999, 29: 520-527. 10.1002/hep.510290232
Geerts A: On the origin of stellate cells: mesodermal, endodermal or neuro-ectodermal?. J Hepatol. 2004, 40: 331-334. 10.1016/j.jhep.2003.12.006
Erkan M, Michalski CW, Rieder S, Reiser-Erkan C, Abiatari I, Kolb A, Giese NA, Esposito I, Friess H, Kleeff J: The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol. 2008, 6: 1155-1161. 10.1016/j.cgh.2008.05.006
Bachem MG, Schunemann M, Ramadani M, Siech M, Beger H, Buck A, Zhou S, Schmid-Kotsas A, Adler G: Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology. 2005, 128: 907-921. 10.1053/j.gastro.2004.12.036
Vonlaufen A, Xu Z, Daniel B, Kumar RK, Pirola R, Wilson J, Apte MV: Bacterial endotoxin: a trigger factor for alcoholic pancreatitis? Evidence from a novel, physiologically relevant animal model. Gastroenterology. 2007, 133: 1293-1303. 10.1053/j.gastro.2007.06.062
Abdollahi A, Hlatky L, Huber PE: Endostatin: the logic of antiangiogenic therapy. Drug Resist Updat. 2005, 8: 59-74. 10.1016/j.drup.2005.03.001
Michalski CW, Erkan M, Sauliunaite D, Giese T, Stratmann R, Sartori C, Giese NA, Friess H, Kleeff J: Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. Br J Cancer. 2008, 99: 760-767. 10.1038/sj.bjc.6604528
Domhan S, Zeier M, Abdollahi A: Immunosuppressive therapy and post-transplant malignancy. Nephrol Dial Transplant. 2008.
Abdollahi A, Schwager C, Kleeff J, Esposito I, Domhan S, Peschke P, Hauser K, Hahnfeldt P, Hlatky L, Debus J: Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci USA. 2007, 104: 12890-12895. 10.1073/pnas.0705505104
Li J, Kleeff J, Kayed H, Felix K, Penzel R, Buchler MW, Korc M, Friess H: Glypican-1 antisense transfection modulates TGF-beta-dependent signaling in Colo-357 pancreatic cancer cells. Biochem Biophys Res Commun. 2004, 320: 1148-1155. 10.1016/j.bbrc.2004.06.063
Domhan S, Muschal S, Schwager C, Morath C, Wirkner U, Ansorge W, Maercker C, Zeier M, Huber PE, Abdollahi A: Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid. Mol Cancer Ther. 2008, 7: 1656-1668. 10.1158/1535-7163.MCT-08-0193
Abdollahi A, Hahnfeldt P, Maercker C, Grone HJ, Debus J, Ansorge W, Folkman J, Hlatky L, Huber PE: Endostatin's antiangiogenic signaling network. Mol Cell. 2004, 13: 649-663. 10.1016/S1097-2765(04)00102-9
Erkan M, Kleeff J, Esposito I, Giese T, Ketterer K, Buchler MW, Giese NA, Friess H: Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene. 2005, 24: 4421-4432. 10.1038/sj.onc.1208642
Reiser-Erkan C, Erkan M, Pan Z, Bekasi S, Giese NA, Streit S, Michalski CW, Friess H, Kleeff J: Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma. Cancer Biol Ther. 2008, 7: 1352-1359.
Erkan M, Kleeff J, Gorbachevski A, Reiser C, Mitkus T, Esposito I, Giese T, Buchler MW, Giese NA, Friess H: Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology. 2007, 132: 1447-1464. 10.1053/j.gastro.2007.01.031
Kota J, Caceres N, Constantinescu SN: Aberrant signal transduction pathways in myeloproliferative neoplasms. Leukemia. 2008, 22: 1828-1840. 10.1038/leu.2008.236
McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, Basecke J, Libra M, Stivala F, Milella M, Tafuri A: Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia. 2008, 22: 708-722. 10.1038/leu.2008.27
Katoh M: WNT/PCP signaling pathway and human cancer (review). Oncol Rep. 2005, 14: 1583-1588.
Wu Q, Maniatis T: Large exons encoding multiple ectodomains are a characteristic feature of protocadherin genes. Proc Natl Acad Sci USA. 2000, 97: 3124-3129. 10.1073/pnas.060027397
Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA: Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest. 2006, 116: 1955-1962. 10.1172/JCI26532
Jaster R, Hilgendorf I, Fitzner B, Brock P, Sparmann G, Emmrich J, Liebe S: Regulation of pancreatic stellate cell function in vitro: biological and molecular effects of all-trans retinoic acid. Biochem Pharmacol. 2003, 66: 633-641. 10.1016/S0006-2952(03)00390-3
Pinzani M: Pancreatic stellate cells: new kids become mature. Gut. 2006, 55: 12-14. 10.1136/gut.2005.074427
Gelse K, Poschl E, Aigner T: Collagens--structure, function, and biosynthesis. Adv Drug Deliv Rev. 2003, 55: 1531-1546. 10.1016/j.addr.2003.08.002
Iyama K, Sumiyoshi H, Khaleduzzaman M, Matsuo N, Ninomiya Y, Yoshioka H: Differential expression of two exons of the alpha1(XI) collagen gene (Col11a1) in the mouse embryo. Matrix Biol. 2001, 20: 53-61. 10.1016/S0945-053X(00)00130-X
Lui VC, Kong RY, Nicholls J, Cheung AN, Cheah KS: The mRNAs for the three chains of human collagen type XI are widely distributed but not necessarily co-expressed: implications for homotrimeric, heterotrimeric and heterotypic collagen molecules. Biochem J. 1995, 311 (Pt 2): 511-516.
So CL, Kaluarachchi K, Tam PP, Cheah KS: Impact of mutations of cartilage matrix genes on matrix structure, gene activity and chondrogenesis. Osteoarthritis Cartilage. 2001, 9 (Suppl A): S160-173.
Yoshioka H, Greenwel P, Inoguchi K, Truter S, Inagaki Y, Ninomiya Y, Ramirez F: Structural and functional analysis of the promoter of the human alpha 1(XI) collagen gene. J Biol Chem. 1995, 270: 418-424. 10.1074/jbc.270.1.418
Yoshioka H, Iyama K, Inoguchi K, Khaleduzzaman M, Ninomiya Y, Ramirez F: Developmental pattern of expression of the mouse alpha 1 (XI) collagen gene (Col11a1). Dev Dyn. 1995, 204: 41-47.
Annunen S, Korkko J, Czarny M, Warman ML, Brunner HG, Kaariainen H, Mulliken JB, Tranebjaerg L, Brooks DG, Cox GF: Splicing mutations of 54-bp exons in the COL11A1 gene cause Marshall syndrome, but other mutations cause overlapping Marshall/Stickler phenotypes. Am J Hum Genet. 1999, 65: 974-983. 10.1086/302585
Griffith AJ, Sprunger LK, Sirko-Osadsa DA, Tiller GE, Meisler MH, Warman ML: Marshall syndrome associated with a splicing defect at the COL11A1 locus. Am J Hum Genet. 1998, 62: 816-823. 10.1086/301789
Li Y, Lacerda DA, Warman ML, Beier DR, Yoshioka H, Ninomiya Y, Oxford JT, Morris NP, Andrikopoulos K, Ramirez F: A fibrillar collagen gene, Col11a1, is essential for skeletal morphogenesis. Cell. 1995, 80: 423-430. 10.1016/0092-8674(95)90492-1
Seegmiller R, Fraser FC, Sheldon H: A new chondrodystrophic mutant in mice. Electron microscopy of normal and abnormal chondrogenesis. J Cell Biol. 1971, 48: 580-593. 10.1083/jcb.48.3.580
Michalski CW, Gorbachevski A, Erkan M, Reiser C, Deucker S, Bergmann F, Giese T, Weigand M, Giese NA, Friess H, Kleeff J: Mononuclear cells modulate the activity of pancreatic stellate cells which in turn promote fibrosis and inflammation in chronic pancreatitis. J Transl Med. 2007, 5: 63- 10.1186/1479-5876-5-63
Michalski CW, Maier M, Erkan M, Sauliunaite D, Bergmann F, Pacher P, Batkai S, Giese NA, Giese T, Friess H, Kleeff J: Cannabinoids reduce markers of inflammation and fibrosis in pancreatic stellate cells. PLoS ONE. 2008, 3: e1701. 10.1371/journal.pone.0001701
Apte MV, Haber PS, Darby SJ, Rodgers SC, McCaughan GW, Korsten MA, Pirola RC, Wilson JS: Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis. Gut. 1999, 44: 534-541. 10.1136/gut.44.4.534
Bachem MG, Zhou Z, Zhou S, Siech M: Role of stellate cells in pancreatic fibrogenesis associated with acute and chronic pancreatitis. J Gastroenterol Hepatol. 2006, 21 (Suppl 3): S92-96. 10.1111/j.1440-1746.2006.04592.x
This work was supported in part by National Aeronautics and Space Administration Specialized Center of Research NNJ04HJ12G, German Krebshilfe (Deutsche Krebshilfe, 107691), DFG National Priority Research Program the Tumor-Vessel Interface "SPP1190", Dietmar Hopp Stiftung awarded to JK and NAG, 03NUK004A/C and by a grant from the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung - BMBF - ME and JK) within the "National Genome Research Network" (NGFN-Plus; 01GS08115).
We thank Barbara Schwager and Claudia Rittmüller for their excellent technical assistance with the microarray analysis.
Study concept and design: ME, HF, JD, PEH, AA, JK; acquisition of data: NW, TS, ZP, CS, XJ, UW, NAG, WA; analysis and interpretation of data: ME, CS, WA, AA, JK; drafting of the manuscript: ME, AA, JK; critical revision of the manuscript for important intellectual content JD, PEH, HF; statistical analysis: CS; obtained funding: NAG, PEH, AA, ME, JK; technical and material support: NAG, JD; study supervision: AA, JK. All authors have read and approved the final manuscript.
Amir Abdollahi and Jörg Kleeff contributed equally to this work.
Electronic supplementary material
Additional file 1:Expression profile of stellate cells for typical markers. The purity of the stellate cell population was routinely checked by immunocytochemistry and immunofluorescence analyses at every passage used. Cells were seeded on Teflon covered slides, fixed, permeabilized and immunostained with specific antibodies against α-SMA, collagen type-Ia, fibronectin, periostin, collagen XVIII and VEGF as published before . Contamination profiling for cancer cells was made by a specific antibody against Pan-cytokeratin. Non-immunized IgG was used appropriately as negative control (original magnification: 200-400×). (PDF 248 KB)
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Erkan, M., Weis, N., Pan, Z. et al. Organ-, inflammation- and cancer specific transcriptional fingerprints of pancreatic and hepatic stellate cells. Mol Cancer 9, 88 (2010). https://doi.org/10.1186/1476-4598-9-88
- Chronic Pancreatitis
- Pancreatic Cancer Cell
- Stellate Cell
- Hepatic Stellate Cell
- Pancreatic Ductal Adenocarcinoma